Who Paid My Doc
James Rittimann
Vascular & Interventional Radiology Tulsa, OK Medical Doctor
NPI 1396973434 CMS profile 1325122
4111 S Darlington Ave, Ste 700, Tulsa, OK 74135
General payments
$9,573
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, James Rittimann of Tulsa, OK is reported in the CMS Open Payments database as having received $9,573 across 102 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 76th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,789 | 29 | |
| 2024 | General | $1,610 | 16 | |
| 2023 | General | $136 | 4 | |
| 2022 | General | $1,771 | 16 | |
| 2021 | General | $69 | 4 | |
| 2020 | General | $1,507 | 17 | |
| 2019 | General | $1,691 | 16 |
Beside peers
- James Rittimann
- Vascular & Interventional Radiology median
- Middle half of Vascular & Interventional Radiology
- National median
In program year 2025, general payments to James Rittimann were reported at $2,789. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.
Show as a table
| Year | James Rittimann | Vascular & Interventional Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,691 | $422 | $125–$1,555 | $163 |
| 2020 | $1,507 | $200 | $68–$652 | $114 |
| 2021 | $69 | $280 | $99–$866 | $132 |
| 2022 | $1,771 | $433 | $137–$1,497 | $149 |
| 2023 | $136 | $506 | $152–$2,019 | $160 |
| 2024 | $1,610 | $556 | $175–$1,930 | $164 |
| 2025 | $2,789 | $534 | $166–$2,075 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 219 billing codesPaid by Medicare
$133,892
Medicare patients
1,997
Services billed
3,312
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 65% | |
| Ischemic heart disease | 48% | |
| Diabetes | 42% | |
| Chronic kidney disease | 39% | |
| Heart failure | 37% | |
| COPD | 33% | |
| Atrial fibrillation | 32% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
102 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Vascular & Interventional Radiology in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Vascular & Interventional Radiology
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.